Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO 10/23/2018 Medications, CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 22, 2018-- Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic...